Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NFC-1 in 22q11.2 Deletion Syndrome
NCT02895906Phase 1Completed
- Sponsor
- Avalo Therapeutics
- Start
- Nov 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fasoracetam in 22q11.2 deletion syndrome (22qDS), sponsored by Avalo Therapeutics. Primary endpoint: Time to symptom relapse at 5 weeks. Started Nov 2016; status: completed.
02
Drugs
fasoracetam
03
Conditions
22q11.2 deletion syndrome (22qDS)
Beyond the preview
Go deeper on NCT02895906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02895906.